保留胸大肌筋膜对接受保乳性乳房切除术并即刻乳房再造的乳腺癌患者长期肿瘤学结局无影响:倾向性评分匹配分析
本研究纳入2014—2019年在本中心接受保乳性乳房切除术联合肌下即刻假体乳房再造的早期乳腺癌女性,采用倾向性评分匹配形成保留筋膜组与切除筋膜组各219例,比较两组长期肿瘤学结局。中位随访约64.8个月,两组无局部区域复发生存、无病生存、无远处转移生存和总生存均无显著差异,保留胸大肌筋膜未显著影响长期肿瘤学结局。
要点
- 匹配后保留筋膜组与切除筋膜组各219例,随访约64.8个月。
- 两组无局部区域复发生存、无病生存、无远处转移生存和总生存均无显著差异。
- 保留筋膜组61.5%的局部区域复发事件发生在术后2年内。
核心结论
- 保留胸大肌筋膜未显著影响接受保乳性乳房切除术并即刻假体乳房再造的乳腺癌患者的长期肿瘤学结局。
- 对于无肿瘤可疑侵犯该筋膜的乳腺癌患者,保留胸大肌筋膜可能是安全的。
研究设计与样本
- 本研究为倾向性评分匹配分析,纳入2014—2019年在本中心接受保乳性乳房切除术联合肌下即刻假体乳房再造的早期乳腺癌女性。
- 采用倾向性评分匹配方法形成保留筋膜组与切除筋膜组,匹配后每组219例。
- 采用Kaplan-Meier法计算无局部区域复发生存、无病生存、无远处转移生存和总生存率,并用log-rank检验比较两组。
主要发现
- 保留筋膜组平均随访64.8±18.1个月,切除筋膜组平均随访64.9±18.4个月。
- 无局部区域复发生存率:保留筋膜组91.3% vs 切除筋膜组93.8%(p=0.818),两组无显著差异。
- 无远处转移生存率:保留筋膜组94.0% vs 切除筋膜组92.3%(p=0.056),两组无显著差异。
- 无病生存率:保留筋膜组89.9% vs 切除筋膜组88.4%(p=0.261),两组无显著差异。
- 总生存率:保留筋膜组95.8% vs 切除筋膜组95.4%(p=0.783),两组无显著差异。
临床怎么用
- 对于无肿瘤可疑侵犯胸大肌筋膜的乳腺癌患者,保留胸大肌筋膜可能是安全的。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The oncologic safety of preserving the pectoralis major fascia (PMF) in patients with breast cancer remains controversial. In this study, we aimed to determine the impact of preserving the PMF on long-term oncologic outcomes in patients with breast cancer treated with immediate implant-based breast reconstruction (IBBR) following conservative mastectomy. METHODS: We selected women with early-stage breast cancer who underwent conservative mastectomy and submuscular IBBR in our center during 2014-2019. The propensity score matching method was used to create well-balanced fascia-preserved and fascia-removed groups. Locoregional recurrence-free survival (LRFS), disease-free survival (DFS), distant metastasis-free survival (DMFS), and overall survival (OS) rates were calculated using the Kaplan-Meier method and compared using log-rank tests between the fascia-preserved and fascia-removed groups. RESULTS: After matching, there were 219 patients in each group. The mean follow-up time was 64.8 ± 18.1 months for the fascia-preserved group and 64.9 ± 18.4 months for the fascia-removed group. There were no significant differences between the groups in terms of LRFS (91.3% vs. 93.8%; p = 0.818), DMFS (94.0% vs. 92.3%; p = 0.056), DFS (89.9% vs. 88.4%; p = 0.261), and OS (95.8% vs. 95.4%; p = 0.783) rates. In the fascia-preserved group, 61.5% of the locoregional recurrence events occurred within 2 years after surgery. CONCLUSION: Preservation of the PMF did not significantly impact the long-term oncologic outcomes in patients with breast cancer who underwent conservative mastectomy and IBBR. The PMF might be safely preserved in patients without suspicious tumor invasion into this fascia.
引用
- Chen AX, Li XX, Guo ZY, et al. Preservation of the pectoralis major fascia has no impact on the long-term oncologic outcomes of patients with breast cancer treated with conservative mastectomy and immediate breast reconstruction: A propensity score matching analysis. J Plast Reconstr Aesthet Surg. 2023. PMID: 37782996. doi:10.1016/j.bjps.2023.09.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。